Evidence map›Paper›PMID 36376216›Full record

ArticleVaccine2023

Short-term safety of COVID-19 mRNA vaccines with respect to all-cause mortality in the older population in Norway.

Paz Lopez-Doriga Ruiz, Nina Gunnes, Jon Michael Gran, Øystein Karlstad, Randi Selmer, Jesper Dahl, Håkon Bøås, Richard Aubrey White, Aurora Christine Hofman, Trine Hessevik Paulsen and 5 more

Open access · hybridAbstract read
In one paragraph

Article in Vaccine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
1.9field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.

  1. Questionable robustness in the findings of a meta-analysis.Human vaccines & immunotherapeutics · 2023
    Pooled it
  2. Observational
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 1 country.

Paz Lopez-Doriga RuizNorwegian Institute of Public Health, Oslo, Norway; Oslo University Hospital, Oslo, Norway. Electronic address: Paz.Lopez-Doriga.Ruiz@fhi.no.
Nina GunnesNorwegian Institute of Public Health, Oslo, Norway; Oslo University Hospital, Oslo, Norway.
Jon Michael GranOslo Centre for Biostatistics and Epidemiology, University of Oslo and Oslo University Hospital, Oslo, Norway.
Øystein KarlstadNorwegian Institute of Public Health, Oslo, Norway.
Randi SelmerNorwegian Institute of Public Health, Oslo, Norway.
Jesper DahlNorwegian Institute of Public Health, Oslo, Norway.
Håkon BøåsNorwegian Institute of Public Health, Oslo, Norway.
Richard Aubrey WhiteNorwegian Institute of Public Health, Oslo, Norway.
Aurora Christine HofmanNorwegian Institute of Public Health, Oslo, Norway.
Trine Hessevik PaulsenNorwegian Institute of Public Health, Oslo, Norway.
Sara Viksmoen WatleNorwegian Institute of Public Health, Oslo, Norway.
Anette Hylen RanhoffNorwegian Institute of Public Health, Oslo, Norway; Department of Clinical Science, University of Bergen, Bergen, Norway.
Geir BukholmNorwegian Institute of Public Health, Oslo, Norway.
Hanne Løvdal GulsethNorwegian Institute of Public Health, Oslo, Norway.
German TapiaNorwegian Institute of Public Health, Oslo, Norway.
Norwegian Institute of Public Health · NOOslo University Hospital · NOUniversity of Bergen · NOUniversity of Oslo · NO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThere have been concerns about COVID-19 vaccination safety among frail older individuals. We investigated the relationship between COVID-19 mRNA vaccination and mortality among individuals aged ≥ 70 years and whether mortality varies across four groups of health services used.

methodsIn this nationwide cohort study, we included 688,152 individuals aged ≥ 70 years at the start of the Norwegian vaccination campaign (December 27, 2020). We collected individual-level data from theNorwegian Emergency Preparedness Register for COVID-19. Vaccinated and unvaccinated individuals were matched (1:1 ratio) on the date of vaccination based on sociodemographic and clinical characteristics. The main outcome was all-cause mortality during 21 days after first dose of COVID-19 mRNA vaccination. Kaplan-Meier survival functions were estimated for the vaccinated and unvaccinated groups. We used Cox proportional-hazards regression to estimate hazard ratios (HRs) of death between vaccinated and unvaccinated individuals, with associated 95% confidence intervals (CIs), overall and by use of health services (none, home-based, short- and long-term nursing homes) and age group.

resultsBetween December 27, 2020, and March 31, 2021, 420,771 older individuals (61.1%) were vaccinated against COVID-19. The Kaplan-Meier estimates based on the matched study sample showed a small absolute risk difference in all-cause mortality between vaccinated and unvaccinated individuals, with a lower mortality in the vaccinated group (overall HR 0.28 [95% CI: 0.24-0.31]). Similar results were obtained in analyses stratified by use of health services and age group.

conclusionWe found no evidence of increased short-term mortality among vaccinated individuals in the older population after matching on sociodemographic and clinical characteristics affecting vaccination and mortality.

Indexed as

COVID-19COVID-19 VaccinesCohort StudiesHumansmRNA VaccinesNorwayRNA, MessengerVaccinationCOVID-19 VaccinesmRNA VaccinesRNA, MessengerCOVID-19 vaccineElderlySide-effects

Identifiers

PMID36376216
PMCPMC9637531
OpenAlexW4308449574

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.